Donna Krupa
(301) 634-7209
dkrupa@the-aps.org
Erectile Dysfunction In Diabetes Is Due To Selective Defect In The Brain
Defect is result of a loss of synthetic enzyme, animal study finds
BETHESDA, MD – A new study sheds additional light on how erectile dysfunction (ED) interacts with diabetes. The study is another step in uncovering the link between the two disorders, and may lead to improved efficacy in treatments.
The study, “Lack of Central Nitric Oxide Triggers Erectile Dysfunction in Diabetes,” was conducted by Hong Zheng, William G. Mayhan, and Kaushik P. Patel, Departments of Cellular and Integrative Physiology; and Keshore R. Bidasee, Department of Pharmacology, University of Nebraska Medical Center, Omaha, NE. The results appear in the March 2007 edition of the American Journal of Physiology – Regulatory, Integrative and Comparative Physiology, one of 11 peer-reviewed scientific publications issued monthly by The American Physiological Society (APS) (www.The-APS.org).
Background
Sexual dysfunction is a well-recognized consequence of diabetes mellitus in men. Erectile dysfunction, retrograde ejaculation and the loss of seminal emission have all been described by such patients. This study examined induced penile erection, yawning and stretch in diabetic rats. Male Sprague-Dawley rats treated with streptozotocin (STZ) to induce diabetes were used as they exhibit sexual and behavioral symptoms similar to those found in diabetic men with sexual dysfunction.
The researchers focused on the paraventricular nucleus (PVN) of the hypothalamus, located in the brain, an integration center between the central and peripheral nervous systems. The site is involved in numerous functions, including erectile function and sexual behavior, and is a primary site within the forebrain that has been implicated in penile erection. The investigators also examined central nitric oxide (NO within the PVN) which plays an important role in the neurotransmission of normal penile erection.
Penile erection is a behavioral response that occurs in response to the administration of N-methyl-D-aspartic acid (NMDA) within the PVN. At the same time, inhibition of NO synthase with NG-monomethly-L-argining (L-NMMA) prevents NMDA-induced erection. The researchers hypothesized that the blunted NMDA mediated responses in diabetes reflects an impaired NO mechanism within the PVN. The involvement of an NO mechanism in the NMDA mediated behavioral response was also explored.
Methodology
The rats were exposed to a light/dark cycle, with standard temperature and humidity levels. The animals were randomly selected to receive chemical injection of the streptozotocin (STZ) to induce diabetes. Those rats that did not receive STZ (vehicle injected) served as controls. The experiments began on each of the rats four weeks after the injections.
Four experiments were conducted. Experiment one examined the effect of L-NMMA on NMDA mediated behavioral responses in normal rats; experiment two measured behavioral responses to NMDA or sodium nitroprusside (SNP), an NO donor in both control and diabetic rats; the third experiment observed the effect of diabetes on nNOS protein in the PVN; the fourth experiment measured NMDA mediated behavioral responses in diabetic rats after restoring the nNOS protein in the PVN using viral gene transfer.
Results
The researchers found that:
- when L-NMMA was used to block NO production in the PVN, NMDA mediated penile erectile responses were blunted
- NMDA-induced erections were significantly blunted in diabetic rats compared with control rats
- the nNOS protein levels in the PVN were decreased in rats with diabetes and
- restoring nNOS protein within the PVN of diabetic rats with viral gene transfer could alleviate the blunted NMDA induced erectile responses.
Conclusion
The researchers conclude that erectile dysfunction in diabetes is due to a selective defect in the NO mechanisms within the PVN. This defect is a loss in the synthetic enzyme for the production of NO within the neurons of the PVN. Restoring this synthetic enzyme may have a significant therapeutic value for diabetic patients with ED.
###
JOURNAL PUBLICATION INFORMATION: American Journal of Physiology – Regulatory, Integrative and Comprehensive Physiology – March 2007.
Exercising Harder—and Shorter—Can Help Type 2 Diabetes
Released December 12, 2011 - Regular exercise has proven benefits in preventing and treating type 2 diabetes, but many patients find it tough to meet the American Diabetes Association guidelines of 150 minutes of moderate to vigorous exercise a week. A new study suggests that there could be a better way. In a small proof-of-principle study in eight type 2 diabetes patients, the researchers found that exercising at a very high intensity, but for a mere 30 minutes a week within a 75 minute total time commitment, lowered overall blood sugar concentrations, reduced post-meal blood sugar spikes, and increased skeletal mitochondrial capacity, a marker of metabolic health. The findings suggest that exercising harder, but in a significantly shorter amount of time, could provide benefits similar to longer, but more moderate, activity.
A Human Hormone Blocker is Found to Help Prevent Obesity & Diabetes During Animal Testing
Released January 3, 2008 - A new study finds that a chemical found in the body is capable of promoting weight loss, improving insulin resistance and reversing diabetes in an animal model. The hormone is gastric inhibitory polypeptide (GIP) receptor blockade.
Exercise Helps Ease Premature Cardiovascular Aging Caused by Type 2 Diabetes
Released October 10, 2012 - Exercise helps attenuate the premature cardiovascular aging that type 2 diabetes can cause.
The “Female Advantage” In Kidney Disease Doesn't Extend To Diabetic Women
Released August 8, 2007 - Women have a “female advantage” when it comes to chronic kidney disease. When compared to men, they have fewer and less severe episodes throughout most of their lives. That advantage disappears, however, when the woman is diabetic. For reasons still unclear, diabetic women are diagnosed with kidney and heart diseases almost as frequently as men. What is it about diabetes that predisposes a woman to develop renal disease at levels generally associated with her male counterpart? Researchers at Georgetown University’s Center for the Study of Sex Differences in Health, Aging and Disease have identified a novel observation to help explain why.
Gender, Coupled With Diabetes, Affects Vascular Disease Development
Released August 15, 2007 - Diabetes is associated with the development of vascular (blood vessel) disease. As we age, vascular disease becomes more common. It has been thought that females may be more susceptible to the earlier development of vascular disease, as vascular changes are observed in females long before any significant development occurs in males. Now, a team of Georgetown University researchers has determined that the vascular activities in diabetic animals vary according to sex. This discovery may eventually have implications for the way males and females are treated medically in the future.